ライフサイエンスコーパス: tretinoin

1 duction of the inhibitor was not affected by tretinoin.

2 e significantly enforced through addition of tretinoin.

3 omized trial of 207 patients, treatment with tretinoin 0.025% gel reduced acne lesion counts at 12 we

4 Topical therapies such as retinoids (eg, tretinoin, adapalene), benzoyl peroxide, azelaic acid, a

5 ted following all-trans retinoic acid (atRA; tretinoin) administration, and a miR-340-5p inhibitor re

6 Pretreatment of skin with tretinoin (all-trans-retinoic acid) inhibited the induct

7 one year of maintenance therapy with either tretinoin alone or in combination with methotrexate and

8 Retinoic-acid receptors specifically bind tretinoin and alitretinoin, whereas retinoid-X receptors

9 The proportions of the tretinoin and control groups who developed a BCC at 5 ye

10 RA apparently results in greater exposure to tretinoin and for a longer time.

11 NFRSF11A, and in the pathways related to the tretinoin and H3K27me3 markers.

12 In some studies, tretinoin and its vehicle were applied to skin under occ

13 ose of currently marketed topical retinoids: tretinoin and tazarotene.

14 s less pronounced with acitretin compared to tretinoin- and tazarotene-containing formulations, sugge

15 A similar effect was observed in tretinoin- and tazarotene-treated mice.

16 despite maintenance L-ATRA and similarity in tretinoin AUC on days 1 and 85, and the other at 5 month

17 131 veterans in the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial.

18 cted the randomized Veterans Affairs Topical Tretinoin Chemoprevention Trial of high-dose topical tre

19 cinoma (BCC) in the Veterans Affairs topical tretinoin chemoprevention trial, which included individu

20 In contrast to the decline in tretinoin concentration seen within 3 to 4 days of admin

21 es between the area under the curve (AUC) of tretinoin concentration versus time on day 1 and day 15

22 Because serum tretinoin concentrations are higher, and maintained long

23 PL to either a standard induction regimen of tretinoin, cytarabine, and daunorubicin, followed by 2 c

24 n Chemoprevention Trial of high-dose topical tretinoin for KC prevention.

25 of life difference was worse symptoms in the tretinoin group at 12 months after randomization.

26 using the in vivo mouse model further proved tretinoin had a better synergistic effect to increase su

27 Topical tretinoin has been used for KC chemoprevention, although

28 Topical therapy including tretinoins, hydroxy acids, bleaching agents, and sunscre

29 nd all-trans retinoic acid (atRA, designated tretinoin in medical products), demonstrated a requireme

30 Treatment with topical tretinoin inhibits irradiation-induced matrix metallopro

31 patients demonstrates that high-dose topical tretinoin is ineffective at reducing risk of KCs.

32 ed signaling with small molecules, including tretinoin, metformin, or TR4-shRNAs, all led to increase

33 et al. assessed the effects of 0.1% topical tretinoin on NMSC.

34 We randomized 1,131 patients to topical 0.1% tretinoin or a matching vehicle control for 1.5-5.5 year

35 d by 2 courses of consolidation therapy with tretinoin plus daunorubicin, or to the same induction an